Charles River Laboratories reported $4.00B of revenue over the trailing twelve months, −0.74% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.00B (to Q2 2026). Net income: −$238M, trailing twelve months to Q2 2026. Free cash flow: $371M, trailing twelve months to Q2 2026. Operating margin: 2.2%, trailing twelve months to Q2 2026.

CRLCharles River Laboratories

Healthcare

$301.83+92% 1Y

$301.83

$145.5752 weeks$310.95

CRL as reported

Charles River Laboratories reported $4.00B of revenue over the trailing twelve months, −0.74% on the year before. 11 reported series are charted on this page, each one as filed.

$4.00B

Revenue, trailing twelve months · to Q2 2026 · −0.74% against the twelve months before

Net income: −$238M
Net income · +256% year on year · trailing twelve months to Q2 2026
Free cash flow: $371M
Free cash flow · −36% year on year · trailing twelve months to Q2 2026
Operating margin: 2.2%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CRL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.00B	−0.74%	Q2 2026
Net income	−$238M	+256%	Q2 2026
EPS	−$4.79	+274%	Q2 2026
Gross margin	37%	n/a	Q4 2020 · 22 quarters behind
Operating margin	2.2%	n/a	Q2 2026
Net margin	−6.0%	n/a	Q2 2026
ROE	−5.4%	n/a	Q2 2026
ROA	−2.2%	n/a	Q2 2026
ROIC	1.2%	n/a	Q2 2026
Free cash flow	$371M	−36%	Q2 2026
P/E	26.7	n/a	Q3 2024 · 7 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.